BIOMAT Database Logo BIOMAT Database Logo

Preventive effect of a new immunosuppressant FK-506 on insulitis and diabetes in non-obese diabetic mice. 1990

J Miyagawa, and K Yamamoto, and T Hanafusa, and N Itoh, and C Nakagawa, and A Otsuka, and H Katsura, and K Yamagata, and A Miyazaki, and N Kono
Second Department of Internal Medicine, Osaka University Medical School, Japan.

We investigated the effect of an immunosuppressant FK-506 on histological change of islets, the onset of diabetes, and the change of spleen cell subsets in female non-obese diabetic mice. Mice administered intraperitoneally with FK-506 from 5 to 20 weeks of age showed marked suppression of mononuclear cell infiltration (insulitis) at 10 weeks of age. Among the subsets of the spleen cells, a significant decrease in the population of Thyl.2-positive T cells (pan-T), L3T4-positive T cells (mainly helper/inducer), and Lyt2-positive T cells (mainly suppressor/cytotoxic) was observed in FK-506-treated mice. Furthermore, glucose tolerance of the mice at 15 weeks of age was clearly improved. Cumulative incidence observed up to 40 weeks of age was 86% in control mice and 23% in FK-506-treated mice (p less than 0.01). These data indicate that FK-506 has a preventive effect on insulitis and diabetes by the suppression of cell-mediated autoimmunity in non-obese diabetic mice.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008820 Mice, Obese Mutant mice exhibiting a marked obesity coupled with overeating, hyperglycemia, hyperinsulinemia, marked insulin resistance, and infertility when in a homozygous state. They may be inbred or hybrid. Hyperglycemic Mice,Obese Mice,Mouse, Hyperglycemic,Mouse, Obese,Hyperglycemic Mouse,Mice, Hyperglycemic,Obese Mouse
D010179 Pancreas A nodular organ in the ABDOMEN that contains a mixture of ENDOCRINE GLANDS and EXOCRINE GLANDS. The small endocrine portion consists of the ISLETS OF LANGERHANS secreting a number of hormones into the blood stream. The large exocrine portion (EXOCRINE PANCREAS) is a compound acinar gland that secretes several digestive enzymes into the pancreatic ductal system that empties into the DUODENUM.
D010182 Pancreatic Diseases Pathological processes of the PANCREAS. Disease, Pancreatic,Diseases, Pancreatic,Pancreatic Disease
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D016559 Tacrolimus A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro. Anhydrous Tacrolimus,FK-506,FK506,FR-900506,Prograf,Prograft,Tacrolimus Anhydrous,Anhydrous, Tacrolimus,FK 506,FR 900506,FR900506,Tacrolimus, Anhydrous
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

J Miyagawa, and K Yamamoto, and T Hanafusa, and N Itoh, and C Nakagawa, and A Otsuka, and H Katsura, and K Yamagata, and A Miyazaki, and N Kono
The immunosuppressant FK-506 prevents progression of diabetes in nonobese diabetic mice.
November 1990, Clinical immunology and immunopathology,
J Miyagawa, and K Yamamoto, and T Hanafusa, and N Itoh, and C Nakagawa, and A Otsuka, and H Katsura, and K Yamagata, and A Miyazaki, and N Kono
Effect of lipoic acid on cyclophosphamide-induced diabetes and insulitis in non-obese diabetic mice.
January 1994, International journal of immunopharmacology,
J Miyagawa, and K Yamamoto, and T Hanafusa, and N Itoh, and C Nakagawa, and A Otsuka, and H Katsura, and K Yamagata, and A Miyazaki, and N Kono
FK-506--a novel immunosuppressant.
June 1993, Annals of the New York Academy of Sciences,
J Miyagawa, and K Yamamoto, and T Hanafusa, and N Itoh, and C Nakagawa, and A Otsuka, and H Katsura, and K Yamagata, and A Miyazaki, and N Kono
Therapeutic effect of a new immunosuppressant, FK-506, on vasospasm after subarachnoid hemorrhage.
June 1993, Neurosurgery,
J Miyagawa, and K Yamamoto, and T Hanafusa, and N Itoh, and C Nakagawa, and A Otsuka, and H Katsura, and K Yamagata, and A Miyazaki, and N Kono
[FK 506, a new immunosuppressant produced by a Streptomyces].
May 1991, Nihon rinsho. Japanese journal of clinical medicine,
J Miyagawa, and K Yamamoto, and T Hanafusa, and N Itoh, and C Nakagawa, and A Otsuka, and H Katsura, and K Yamagata, and A Miyazaki, and N Kono
FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.
September 1987, The Journal of antibiotics,
J Miyagawa, and K Yamamoto, and T Hanafusa, and N Itoh, and C Nakagawa, and A Otsuka, and H Katsura, and K Yamagata, and A Miyazaki, and N Kono
Effects of immunosuppressant FK-506 on tooth movement.
August 2010, Orthodontics & craniofacial research,
J Miyagawa, and K Yamamoto, and T Hanafusa, and N Itoh, and C Nakagawa, and A Otsuka, and H Katsura, and K Yamagata, and A Miyazaki, and N Kono
Maternal obesity exacerbates insulitis and type 1 diabetes in non-obese diabetic mice.
July 2014, Reproduction (Cambridge, England),
J Miyagawa, and K Yamamoto, and T Hanafusa, and N Itoh, and C Nakagawa, and A Otsuka, and H Katsura, and K Yamagata, and A Miyazaki, and N Kono
[Prevention and therapy for diabetes associated with insulitis in non-obese diabetic mice].
July 1982, Horumon to rinsho. Clinical endocrinology,
J Miyagawa, and K Yamamoto, and T Hanafusa, and N Itoh, and C Nakagawa, and A Otsuka, and H Katsura, and K Yamagata, and A Miyazaki, and N Kono
Prevention of insulitis and diabetes in beta 2-microglobulin-deficient non-obese diabetic mice.
September 1994, International immunology,
Copied contents to your clipboard!